TheraCryf Competitors and Similar CompaniesClear all

TheraCryf's competitors and similar companies include AEterna Zentaris, SuperX, Apotex and Sanofi Pasteur.

	TheraCryf TheraCryf (formerly known as Evgen Pharma) is a company that develops therapeutics in oncology and behavioral brain disorders.	AEterna Zentaris AEterna Zentaris is a drug development company specialized in oncology and endocrine therapy. The Companys product pipeline	SuperX SuperX is a virtual biopharmaceutical company developing products to deliver anticoagulation without bleeding.	Apotex Apotex is a company that develops and manufactures pharmaceutical products.	Sanofi Pasteur Sanofi Pasteur is a pharmaceutical company that develops, manufactures, and supplies vaccines.
Founding Date	Founding Date 2007	Founding Date N/A	Founding Date 2016	Founding Date 1974	Founding Date 1989
Type	Type Public	Type Public	Type Private	Type Subsidiary	Type Subsidiary
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare clinics drug development pharma women's health	Tags Healthcare clinics drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma
Locations	Locations Nether Alderley, GB HQ Nether Alderley, GB	Locations Summerville, US HQ Toronto, CA Frankfurt Am Main, DE	Locations Cambridge, GB HQ	Locations Toronto, CA HQ Toronto, CA	Locations Lyon, FR HQ
Employees	Employees 9	Employees 1168% decrease	Employees 12	Employees 6,294	Employees 6,7454% increase
Valuation ($)	Valuation ($) 4.3 m	Valuation ($) 17.5 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $7.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €2.8b (FY, 2021)
Cost of goods	Cost of goods N/A	Cost of goods $4.9m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods €505m (FY, 2021)
Gross profit	Gross profit £34k (FY, 2025)	Gross profit $2.6m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit €2.3b (FY, 2021)
Net income	Net income (£1.9m) (FY, 2025)	Net income ($10.4m) (FY, 2025)	Net income N/A	Net income N/A	Net income €605m (FY, 2021)